Desvenlafaxine for the prevention of relapse in major depressive disorder: Results of a randomized trial

Journal of Clinical Psychopharmacology

Volumn 30, Issue 1, 2010, Pages 18-24

  Rickels, Karl ^a   Montgomery, Stuart A ^b   Tourian, Karen A ^c   Guelfi, Julien D ^d   Pitrosky, Bruno ^c   Padmanabhan, Sudharshan Krishna ^c   Germain, Jean Michael ^c   Leurent, Claire ^c   Brisard, Claudine ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c PFIZER INC   (United States)

^d CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Adverse events; Desvenlafaxine; Major depressive disorder

Indexed keywords

DESVENLAFAXINE; PLACEBO;

ABDOMINAL PAIN; ABNORMAL DREAMING; ADULT; AGED; ANXIETY; ARTICLE; BACKACHE; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EJACULATION; ELECTROCARDIOGRAM; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; IRRITABILITY; LABORATORY TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD CHANGE; MULTICENTER STUDY; MUSCLE SPASM; MYALGIA; NAUSEA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; TREATMENT OUTCOME;

EID: 74549160953     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181c94c4d     Document Type: Article

References (32)

1. Keller MB, Lavori PW, Endicott J, et al. BDouble depression[: two-year follow-up. Am J Psychiatry. 1983;140:689-694.
2. Lavori PW, Keller MB, Mueller TI, et al. Recurrence after recovery in unipolar MDD: an observational follow-up study of clinical predictors and somatic treatment as a mediating factor. Int J Methods Psychiatr Res. 1994;4:211-229.
3. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
4. National Collaborating Centre for Mental Health and National Institute for Health and Clinical Evidence. Depression: Management of Depression in Primary and Secondary Care. London, UK: National Collaborating Centre for Mental Health and National Institute for Health and Clinical Evidence, 2004;Guideline 23, 1-63.
5. American Psychiatric Association. Treating Major Depressive Disorder: A Quick Reference Guide. Arlington, VA: American Psychiatric Association; 2000:1-25.
6. Keller MB, Lavori PW, Lewis CE, et al. Predictors of relapse in major depressive disorder. JAMA. 1983;250:3299-3304.
7. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry. 1992;149:795-800.
8. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653-661.
9. National Institute of Mental Health and National Institutes of Health. Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel. Am J Psychiatry. 1985;142:469-476.
10. Montgomery SA. The need for long-term treatment of depression. Eur Neuropsychopharmacol. 1997;7(suppl 3):S309-S313.
11. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol. 1996;11: 137-145.
12. Simon JS, Aguiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38:249-257.
13. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004;65:328-336.
14. Kocsis JH, Thase ME, Trivedi MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007;68: 1014-1023.
15. Keller MB, Trivedi MH, Thase ME, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry. 2007;68:1246-1256.
16. Muth EA, Moyer JA, Haskins JT, et al. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-199.
17. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657-665.
18. Parker VD, Richards LS, Nichols AI, et al. The absolute bioavailability of an oral sustained-release formulation of desvenlafaxine succinate in healthy subjects. Poster presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting; March 2-5, 2005; Orlando, FL.
19. Wyeth Pharmaceuticals Inc. Pristiq [Package Insert]. Philadelphia, PA; 2008.
20. DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677-688. (Pubitemid 46841850)
21. Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338-347.
22. Ferguson J, Tourian KA, Rosas GR, et al. A 12-month open-label evaluation of long-term safety and efficacy of desvenlafaxine succinate in outpatients with major depressive disorder. Poster presented at: 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA.
23. Hamilton M. Hamilton rating scale for depression. In: Rush AJ, Pincus HA, First MB, et al, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:526-529.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview: the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33
25. Guy W, ed. Clinical Global Impressions. Publication ADM 76-338. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976; 217-222.
26. Bech P. Psychometric developments of the Hamilton Scales: the spectrum of depression, dysthymia, and anxiety. In: Bech P, Coppen A, eds. The Hamilton Scales. Berlin, Germany: Springer-Verlag; 1990:72-79.
27. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982;18:69-77.
28. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77-87.
29. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry. 2006;188:346-353.
30. European Agency for the Evaluation of Medicinal Products. Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Depression. London, UK: European Agency for the Evaluation of Medicinal Products; 2002:1-10.
31. Thase ME. Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? J Clin Psychiatry. 2002; 63(suppl 2):24-28.
32. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000;57:311-317.